Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells.
The adoptive transfer of tumor-reactive T lymphocytes has recently been demonstrated to be an effective means for mediating the regression of experimental intracranial fibrosarcomas. In this study, mice bearing syngeneic intracranial GL261 gliomas were cured by the combination of sublethal whole body irradiation followed by the intravenous transfer of tumor-draining lymph node (LN) T cells activated with anti-CD3 or staphylococcal enterotoxin C2 (SEC2). To further identify the functional effector T cel population in the adoptive immunotherapy, LN T cells were separated into two subsets, based on the level of expression of the cell adhesion molecule CD62L (L-selectin). As few as 5 x 10(5) CD62Llow cells could cure the majority of animals, whereas 2 x 10(6) CD62Lhigh cells were completely ineffective. Moreover, T cells isolated from advanced intracranial tumors were identified to be predominantly CD62Llow. In contrast, spleens contained a mixture of CD62L low and high cells similar to the transferred cell population. T cells in the glioma site were more actively proliferating than those isolated from the spleen. Mice cured of GL261 tumors demonstrated long-term immunologic memory by rejecting intracranial challenges of the original tumor but not an immunologically distinct tumor. Furthermore, despite infiltration of transferred cells into the intracranial tumors, cured mice did not exhibit any apparent neurologic abnormalities during treatment, prolonged follow-up, or after intracranial tumor rechallenge. This study demonstrates the effective treatment of an intracranial murine glioma by the systemic adoptive transfer of activated tumor-draining LN T cells and selective tumor infiltration by the therapeutically active CD62Llow T cells.
Plautz
G E
GE
Center for Surgery Research, Cleveland Clinic Foundation, Ohio 44195, USA.
Touhalisky
J E
JE
Shu
S
S
D019264:Adoptive Transfer; D000818:Animals; D001932:Brain Neoplasms / Q000276:immunology / Q000628:therapy*; D002469:Cell Separation; D005910:Glioma / Q000276:immunology / Q000628:therapy*; D007111:Immunity, Cellular; D007167:Immunotherapy; D019041:L-Selectin / Q000032:analysis*; D008198:Lymph Nodes / Q000473:pathology; D008213:Lymphocyte Activation; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000032:analysis; D016019:Survival Analysis; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D013997:Time Factors
D016693:Receptors, Antigen, T-Cell, alpha-beta; D019041:L-Selectin